News | ACC | March 31, 2022

CathWorks Presents New Data and Latest Innovations at ACC 2022

CathWorks announces the completion of more than 5,000 FFRangio cases globally.


March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio system will be presented by Dr. Guy Witberg from Rabin Medical Center, Petah Tikva, Israel on Sunday, April 3 at the annual American College of Cardiology (ACC) conference in Washington, DC.

Dr. Witberg and his co-investigators in Israel and Japan examined the 1-year clinical outcomes of 492 patients whose treatment decision was based solely on the CathWorks FFRangio System results. "FFRangio has been in use in our cath lab since 2016 and we have taken part in several studies demonstrating its excellent diagnostic performance compared to the gold standard wire-based FFR, culminating in the pivotal FAST-FFR trial and our leading role in conducting a pooled analysis that compared FFRangio to wire-based FFR. Based on the results of these studies, we have been using FFRangio as a standalone tool for physiologic assessment in patients undergoing coronary angiography, and it has become the standard of care in our cath lab replacing wire-based FFR. The data we present at ACC will be the first to examine the clinical outcomes of FFRangio-guided treatment in this population. We are happy to add this outcomes study to the growing body of evidence supporting the broad application of FFRangio in the intraprocedural assessment of patients with coronary artery disease," said Dr. Witberg. 

"CathWorks is grateful for the partnership with the study investigators as we continue to broaden the global clinical adoption of FFRangio and work towards our mission of transforming how cardiovascular disease is diagnosed and treated. We are proud to also announce that we surpassed a major milestone for CathWorks this month with more than 5,000 patients having benefited from our FFRangio technology, and we are determined to help many more," said Ramin Mousavi, President and CEO of CathWorks.

Not only will CathWorks have a prominent presence in the exhibit hall at ACC 2022 where healthcare professionals can get hands-on experience with the latest generation of the CathWorks FFRangio System, its technology will also be showcased at the Future Hub for the duration of the conference. Several scientific sessions at ACC will focus on the growing adoption of angio-based FFR and its role in the management of patients with cardiovascular disease.

ACC.22 will take place April 2-4, 2022, in Washington, DC, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention.

For more information: www.acc.org

Find more ACC22 content here


Related Content

News | FFR Technologies

January 4, 2022 - Pie Medical Imaging (PMI), a global leader in cardiac imaging, part of the Esaote Group, recently ...

Home January 04, 2022
Home
News | FFR Technologies

December 13, 2021 - HeartFlow Inc., the leader in revolutionizing precision heart care, today announced it has submitted ...

Home December 13, 2021
Home
News | FFR Technologies

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation ...

Home November 09, 2021
Home
News | FFR Technologies

November 9, 2021 — Use of a novel technique called the quantitative flow ratio (QFR) to precisely identify and measure ...

Home November 09, 2021
Home
News | FFR Technologies

September 8, 2021 — Adding systematic fractional flow reserve (FFR) assessment to coronary angiography does not reduce ...

Home September 08, 2021
Home
News | FFR Technologies

July 26, 2021 – CathWorks announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the ...

Home July 26, 2021
Home
News | FFR Technologies

July 15, 2021 — HeartFlow, which has commercialized noninvasive computed tomography derived fractional flow reserve (FFR ...

Home July 15, 2021
Home
News | FFR Technologies

June 22, 2021 – Philips Healthcare announced the official start of the DEFINE GPS study, with the first patient being ...

Home June 22, 2021
Home
News | FFR Technologies

May 17, 2021 — In patients who received a coronary stent for an ST-elevation myocardial infarction (STEMI) heart attack ...

Home May 17, 2021
Home
Videos | FFR Technologies

This is an example of the Medis Medical Imaging Quantitative Flow Ratio (QFR) system that offers a fractional flow ...

Home December 16, 2020
Home
Subscribe Now